Observational studyJapanese journal of ophthalmology2022
Long-term results of the safety and effectiveness of a novel microshunt in Japanese patients with primary open-angle glaucoma.
Observational study in Japanese journal of ophthalmology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Comparison of one-year postoperative outcomes between PreserFlo MicroShunt and trabeculectomy in Japanese patients with open angle glaucoma: a retrospective cohort study using propensity score matching.Japanese journal of ophthalmology · 2026Observational
- Preserflo™ microshunt for the treatment of refractory childhood glaucoma: A case series study.American journal of ophthalmology case reports · 2025Article
- Management practices and surgical techniques for ab externo less invasive glaucoma surgery: a literature review and expert recommendations.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Review
- Short-term efficacy and safety of PreserFlo MicroShunt in Japanese patients with medically treated primary open-angle glaucoma.Japanese journal of ophthalmology · 2025Observational
- Preserflo-MicroShunt: Postoperative Effects on Endothelial Cell Density and Corneal Thickness.Biomedicines · 2025Article
- One-Year Comparison of Efficacy and Safety of PreserFlo MicroShunt with Mitomycin C Applied by Sub-Tenon Injection Versus Sponge.Ophthalmology and therapy · 2025Article
- Transient hyphema associated with PRESERFLOScientific reports · 2024Article
- A short-term comparison of surgical results between an ab-externo microshunt and trabeculectomy with a main focus on postoperative corneal astigmatism.Japanese journal of ophthalmology · 2024Article
- [Occlusion of the PreserFlo® MicroShunt implant by iris tissue].Die Ophthalmologie · 2024Article
- Subconjunctival filtration in evolution: current evidence on MicroShunt implantation for treating patients with glaucoma.Eye and vision (London, England) · 2023Review
- Efficacy of the PRESERFLO MicroShunt and a Meta-Analysis of the Literature.Journal of clinical medicine · 2022Article
- Minimally Invasive Glaucoma Surgery: Safety of Individual Devices.Journal of clinical medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeTo evaluate the long-term safety and effectiveness of the Preserflo MicroShunt in Japanese primary open-angle glaucoma (POAG) patients. STUDY
designSingle-site, nonrandomized observational study. PATIENTS AND
methodsEight eyes of 7 POAG patients were included. The surgical complications and interventions were monitored. The preoperative and postoperative intraocular pressures (IOPs), numbers of antiglaucoma medications, logarithm of the minimum angle of resolution visual acuity (VA), mean deviation (MD) slope, and corneal endothelial cell density (CECD) were compared retrospectively.
resultsThe mean follow-up period was 68.9 months (range, 48-76 months). The baseline IOP of 17.9 ± 3.5 mmHg and the number of glaucoma medications of 3.5 ± 0.5 were significantly reduced at subsequent follow-up visits. At 1, 2, 3, 4, 5, and 6 years postoperatively, the IOPs were 13.8 ± 2.9, 12.8 ± 2.3, 12.1 ± 3.2, 12.6 ± 2.5, 12.3 ± 1.0, and 13.5 ± 3.1 mmHg, respectively, with the use of 1.6 ± 1.4, 1.6 ± 1.6, 1.5 ± 1.4, 1.5 ± 1.4, 1.9 ± 1.3, and 2.0 ± 1.1 medications. Postoperative transient hyphema occurred in 1 eye. Postoperative needling was required in 5 eyes, 12 times in total. No eyes showed significant VA decline, except for 1 eye with a severe central visual field defect that existed preoperatively. The preoperative MD slope of - 1.6 ± 1.2 dB/year improved significantly, to - 0.3 ± 0.2 dB/year (P = 0.023), postoperatively. The baseline CECD decreased from 2595 ± 292 to 2478.4 ± 255 postoperatively.
conclusionThe microshunt surgical procedure is safe and effective for Japanese POAG patients.
Indexed as
Identifiers
34988757What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.